Full Text Journal Articles by
Author Nicolas Mottet

Advertisement

Find full text journal articles






Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.

Christian Pfister, Gwenaelle Gravis, Aude Fléchon, Michel Soulié, Laurent Guy, Brigitte Laguerre, Nicolas Mottet, Florence Joly, Yves Allory, Valentin Harter, Stéphane Culine, ,

BACKGROUND:Perioperative chemotherapy (neoadjuvant or adjuvant) has been developed to increase overall survival for nonmetastatic muscle-invasive bladder cancer (MIBC). Retrospective studies or prospective phase II trials have been reported to use dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC). As dd-MVAC has shown higher response rates in ... Read more >>

Eur. Urol. (European urology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Precision Oncology for Metastatic Prostate Cancer: Translation into Practice.

Maria De Santis, Nicolas Mottet, Philip Cornford, Silke Gillessen, ,

While the principles of precision medicine have been readily embraced by all stakeholders, multiple conceptional and structural challenges hinder its broad implementation in clinical practice. PROfound provides the highest level of evidence for the use of a poly(adenosine diphosphate-ribose) polymerase inhibitor in prostate cancer so far. It is an undoubtedly ... Read more >>

Eur. Urol. (European urology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Reply to Francesco Montorsi, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.

Lisa Moris, Nicolas Mottet, Thomas Wiegel, ,

Eur. Urol. (European urology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research.

Muhammad Imran Omar, Monique J Roobol, Maria J Ribal, Thomas Abbott, Paul-Michael Agapow, Sonia Araujo, Alex Asiimwe, Charles Auffray, Irina Balaur, Katharina Beyer, Chiara Bernini, Anders Bjartell, Alberto Briganti, John-Edward Butler-Ransohoff, Riccardo Campi, Marinel Cavelaars, Bertrand De Meulder, Zsuzsanna Devecseri, Marc Dietrich Voss, Konstantinos Dimitropoulos, Susan Evans-Axelsson, Billy Franks, Louise Fullwood, Denis Horgan, Emma Jane Smith, Amit Kiran, Kati Kivinummi, Mark Lambrecht, Doron Lancet, Peter Lindgren, Sara MacLennan, Steven MacLennan, Maria Manuela Nogueira, Fredrik Moen, Maxim Moinat, Kishore Papineni, Christian Reich, Kristin Reiche, Stijn Rogiers, Claudio Sartini, Kees van Bochove, Femke van Diggelen, Mieke Van Hemelrijck, Hein Van Poppel, Jihong Zong, James N'Dow, ,

An amendment to this paper has been published and can be accessed via a link at the top of the paper. ... Read more >>

Nat Rev Urol (Nature reviews. Urology)
[2020, 17(8):482]

Cited: 0 times

View full text PDF listing >>



Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304-6: Prebiopsy MRI: Through the Looking Glass.

Roderick C N van den Bergh, Olivier Rouvière, Theodorus van der Kwast, ,

Eur. Urol. (European urology)
[2020, 78(3):310-313]

Cited: 0 times

View full text PDF listing >>



Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.

Wanling Xie, Meredith M Regan, Marc Buyse, Susan Halabi, Philip W Kantoff, Oliver Sartor, Howard Soule, Donald Berry, Noel Clarke, Laurence Collette, Anthony D'Amico, Richard De Abreu Lourenco, James Dignam, Mario Eisenberger, Nicholas James, Karim Fizazi, Silke Gillessen, Yohann Loriot, Nicolas Mottet, Wendy Parulekar, Howard Sandler, Daniel E Spratt, Matthew R Sydes, Bertrand Tombal, Scott Williams, Christopher J Sweeney, ,

PURPOSE:Recently, we have shown that metastasis-free survival is a strong surrogate for overall survival (OS) in men with intermediate- and high-risk localized prostate cancer and can accelerate the evaluation of new (neo)adjuvant therapies. Event-free survival (EFS), an earlier prostate-specific antigen (PSA)-based composite end point, may further expedite trial completion. METHODS:EFS ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, 38(26):3032-3041]

Cited: 0 times

View full text PDF listing >>



Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts.

Hesham Elghazaly, Nicolas Mottet, Jorge Garcia, Stephane Oudard, Mack Roach, Claude Abbou, Axel Merseburger, Amr Emara, Samir Shehata, Hesham Tawfik, Ola Khorshid, Ahmed Selim, Akram Assem, Khalid Abdelkarim, Lobna Ezz El-Arab, Shouki Bazarbashi, Abbass Omar, Hesham Elwakil, Mohamed Elashry, Mohamed Abou ElFotouh, Tarek Osman, Mai Ezz El Din,

PURPOSE:Advancements in the diagnosis and treatment of prostate cancer (PC) have rapidly progressed through the past years. Various factors should be taken into account while treating individual patients to ensure optimal and careful decision making. The purpose of this consensus review is to summarize the current practice patterns when managing ... Read more >>

World J Urol (World journal of urology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer.

Stefano Fanti, Karolien Goffin, Boris A Hadaschik, Ken Herrmann, Tobias Maurer, Steven MacLennan, Daniela E Oprea-Lager, Wim Jg Oyen, Olivier Rouvière, Nicolas Mottet, Anders Bjartell,

PURPOSE:Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is used for (re)staging prostate cancer (PCa) and as a biomarker for evaluating response to therapy, but lacks established response criteria. A panel of PCa experts in nuclear medicine, radiology, and/or urology met on February 21, 2020, in Amsterdam, The ... Read more >>

Eur. J. Nucl. Med. Mol. Imaging (European journal of nuclear medicine and molecular imaging)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Reply to Fabiana Gregucci, Roberta Carbonara, and Alba Fiorentino's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. Eur Urol 2020;77:614-27.

Lisa Moris, Nicolas Mottet, Thomas Wiegel,

Eur. Urol. (European urology)
[2020, 78(3):e116-e117]

Cited: 0 times

View full text PDF listing >>



Is laterality of congenital diaphragmatic hernia a reliable prognostic factor? French national cohort study.

Anne Pinton, Julia Boubnova, François Becmeur, Pierre Kuhn, Marie-Victoire Senat, Julien Stirnemann, Marianne Capelle, Jonathan Rosenblatt, Jérôme Massardier, Pascal Vaast, Gwenaelle Le Bouar, Amélie Desrumaux, Laure Connant, Laetitia Begue, Benoit Parmentier, Franck Perrotin, Alain Diguet, Guillaume Benoist, Charles Muszynski, Aurélien Scalabre, Norbert Winer, Jean-Luc Michel, Florence Casagrandre-Magne, Jean-Marie Jouannic, Denis Gallot, Perrine Coste Mazeau, Emmanuel Sapin, Alexis Maatouk, Anne-Hélène Saliou, Loïc Sentilhes, Florence Biquard, Nicolas Mottet, Romain Favre, Alexandra Benachi, Nicolas Sananès,

OBJECTIVES:The objective of this study was to assess whether the laterality of congenital diaphragmatic hernia (CDH) was a prognostic factor for neonatal survival. METHODS:This was a cohort study using the French national database of the Reference Center for Diaphragmatic Hernias. The principal endpoint was survival after hospitalization in intensive care. ... Read more >>

Prenat. Diagn. (Prenatal diagnosis)
[2020, 40(8):949-957]

Cited: 0 times

View full text PDF listing >>



Impact of a selective use of episiotomy combined with Couder's maneuver for the perineal protection.

Pierre-Louis Forey, Marine Lallemant, Aude Bourtembourg-Matras, Astrid Eckman-Lacroix, Rajeev Ramanah, Didier Riethmuller, Nicolas Mottet,

PURPOSE:To evaluate the impact of a selective use of episiotomy combined with Couder's maneuver on the incidence of perineal tears in spontaneous term deliveries. METHODS:A comparative, retrospective, mono-centric study in a university maternity unit was designed and included all primiparous women who delivered spontaneously after 37 weeks of gestation in cephalic ... Read more >>

Arch. Gynecol. Obstet. (Archives of gynecology and obstetrics)
[2020, 302(1):77-83]

Cited: 0 times

View full text PDF listing >>



Introducing PIONEER: a project to harness big data in prostate cancer research.

Muhammad Imran Omar, Monique J Roobol, Maria J Ribal, Thomas Abbott, Paul-Michael Agapow, Sonia Araujo, Alex Asiimwe, Charles Auffray, Irina Balaur, Katharina Beyer, Chiara Bernini, Anders Bjartell, Alberto Briganti, John-Edward Butler-Ransohoff, Riccardo Campi, Marinel Cavelaars, Bertrand De Meulder, Zsuzsanna Devecseri, Marc Dietrich Voss, Konstantinos Dimitropoulos, Susan Evans-Axelsson, Billy Franks, Louise Fullwood, Denis Horgan, Emma Jane Smith, Amit Kiran, Kati Kivinummi, Mark Lambrecht, Doron Lancet, Peter Lindgren, Sara MacLennan, Steven MacLennan, Maria Manuela Nogueira, Fredrik Moen, Maxim Moinat, Kishore Papineni, Christian Reich, Kristin Reiche, Stijn Rogiers, Claudio Sartini, Kees van Bochove, Femke van Diggelen, Mieke Van Hemelrijck, Hein Van Poppel, Jihong Zong, James N'Dow, ,

Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) is a European network of excellence for big data in prostate cancer, consisting of 32 private and public stakeholders from 9 countries across Europe. Launched by the Innovative Medicines Initiative 2 and part of the ... Read more >>

Nat Rev Urol (Nature reviews. Urology)
[2020, 17(6):351-362]

Cited: 0 times

View full text PDF listing >>



An international registry for emergent pathogens and pregnancy.

Alice Panchaud, Guillaume Favre, Leo Pomar, Manon Vouga, Karoline Aebi-Popp, David Baud, ,

Lancet (Lancet (London, England))
[2020, 395(10235):1483-1484]

Cited: 1 time

View full text PDF listing >>



Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic.

Christopher J D Wallis, Giacomo Novara, Laura Marandino, Axel Bex, Ashish M Kamat, R Jeffrey Karnes, Todd M Morgan, Nicolas Mottet, Silke Gillessen, Alberto Bossi, Morgan Roupret, Thomas Powles, Andrea Necchi, James W F Catto, Zachary Klaassen,

CONTEXT:The coronavirus disease 2019 (COVID-19) pandemic is leading to delays in the treatment of many urologic cancers. OBJECTIVE:To provide a contemporary picture of the risks from delayed treatment for urologic cancers to assist with triage. EVIDENCE ACQUISITION:A collaborative review using literature published as of April 2, 2020. EVIDENCE SYNTHESIS:Patients with ... Read more >>

Eur. Urol. (European urology)
[2020, 78(1):29-42]

Cited: 3 times

View full text PDF listing >>



Arsenic Trioxide Treatment during Pregnancy for Acute Promyelocytic Leukemia in a 22-Year-Old Woman.

Claire Cochet, Marion Simonet, Julie Cattin, Jean-Patrick Metz, Ana Berceanu, Eric Deconinck, Etienne Daguindau, Françoise Schillinger, Pierre Fenaux, Nicolas Mottet, Yohan Desbrosses,

Acute leukemia during pregnancy is rare (1 for 100000 pregnancies). The association of arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) is known as the best therapy in standard-risk acute promyelocytic leukemia (APL). We describe the first case of a pregnancy with ATRA and ATO reported in the literature. In ... Read more >>

Case Rep Hematol (Case reports in hematology)
[2020, 2020:3686584]

Cited: 0 times

View full text PDF listing >>



Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.

Lisa Moris, Marcus G Cumberbatch, Thomas Van den Broeck, Giorgio Gandaglia, Nicola Fossati, Brian Kelly, Raj Pal, Erik Briers, Philip Cornford, Maria De Santis, Stefano Fanti, Silke Gillessen, Jeremy P Grummet, Ann M Henry, Thomas B L Lam, Michael Lardas, Matthew Liew, Malcolm D Mason, Muhammad Imran Omar, Olivier Rouvière, Ivo G Schoots, Derya Tilki, Roderick C N van den Bergh, Theodorus H van Der Kwast, Henk G van Der Poel, Peter-Paul M Willemse, Cathy Y Yuan, Badrinath Konety, Tanya Dorff, Suneil Jain, Nicolas Mottet, Thomas Wiegel,

CONTEXT:The optimal treatment for men with high-risk localized or locally advanced prostate cancer (PCa) remains unknown. OBJECTIVE:To perform a systematic review of the existing literature on the effectiveness of the different primary treatment modalities for high-risk localized and locally advanced PCa. The primary oncological outcome is the development of distant ... Read more >>

Eur. Urol. (European Urology)
[2020, 77(5):614-627]

Cited: 1 time

View full text PDF listing >>



Management of bladder cancer in older patients: Position paper of a SIOG Task Force.

Nicolas Mottet, Maria J Ribal, Helen Boyle, Maria De Santis, Philippe Caillet, Ananya Choudhury, Tullika Garg, Matthew Nielsen, Patrick Wüthrich, Kilian M Gust, Shahrokh F Shariat, Georgios Gakis,

Median age at bladder cancer (BC) diagnosis is older than for other major tumours. Age should not determine treatment, and patients should be fully involved in decisions. Patients should be screened with Mini-Cog™ for cognitive impairment and the G8 to ascertain need for comprehensive geriatric assessment. In non-muscle invasive disease, ... Read more >>

J Geriatr Oncol (Journal of geriatric oncology)
[2020, 11(7):1043-1053]

Cited: 0 times

View full text PDF listing >>



Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.

Silke Gillessen, Gerhardt Attard, Tomasz M Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G Bristow, Kim N Chi, Noel Clarke, Ian D Davis, Johann de Bono, Charles G Drake, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Christopher P Evans, Stefano Fanti, Felix Y Feng, Karim Fizazi, Mark Frydenberg, Martin Gleave, Susan Halabi, Axel Heidenreich, Daniel Heinrich, Celestia Tia S Higano, Michael S Hofman, Maha Hussain, Nicolas James, Ravindran Kanesvaran, Philip Kantoff, Raja B Khauli, Raya Leibowitz, Chris Logothetis, Fernando Maluf, Robin Millman, Alicia K Morgans, Michael J Morris, Nicolas Mottet, Hind Mrabti, Declan G Murphy, Vedang Murthy, William K Oh, Piet Ost, Joe M O'Sullivan, Anwar R Padhani, Chris Parker, Darren M C Poon, Colin C Pritchard, Robert E Reiter, Mack Roach, Mark Rubin, Charles J Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I Scher, Neal Shore, Eric Small, Matthew Smith, Howard Soule, Cora N Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Christopher Sweeney, Matthew R Sydes, Mary-Ellen Taplin, Bertrand Tombal, Levent Türkeri, Inge van Oort, Almudena Zapatero, Aurelius Omlin,

BACKGROUND:Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some of these topics to supplement guidelines that are based on ... Read more >>

Eur. Urol. (European urology)
[2020, 77(4):508-547]

Cited: 3 times

View full text PDF listing >>



[Management of residual masses of testis germ cell tumors].

Lancelot Tremeau, Nicolas Mottet,

A residual mass (RM) is an abnormal image with a transverse axis of more than 1cm trans that remains visible on the CT scan performed after chemotherapy for metastatic germ cell tumors. Their management depends on the histology of the initial tumor. In the case of a non-seminomatous germ cell ... Read more >>

Bull Cancer (Bulletin du cancer)
[2020, 107(2):215-223]

Cited: 0 times

View full text PDF listing >>



EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study).

Thomas B L Lam, Steven MacLennan, Peter-Paul M Willemse, Malcolm D Mason, Karin Plass, Robert Shepherd, Ruud Baanders, Chris H Bangma, Anders Bjartell, Alberto Bossi, Erik Briers, Alberto Briganti, Karel T Buddingh, James W F Catto, Maurizio Colecchia, Brett W Cox, Marcus G Cumberbatch, Jeff Davies, Niall F Davis, Maria De Santis, Paolo Dell'Oglio, André Deschamps, James F Donaldson, Shin Egawa, Christian D Fankhauser, Stefano Fanti, Nicola Fossati, Giorgio Gandaglia, Silke Gillessen, Nikolaos Grivas, Tobias Gross, Jeremy P Grummet, Ann M Henry, Alexandre Ingels, Jacques Irani, Michael Lardas, Matthew Liew, Daniel W Lin, Lisa Moris, Muhammad Imran Omar, Karl H Pang, Catherine C Paterson, Raphaële Renard-Penna, Maria J Ribal, Monique J Roobol, Morgan Rouprêt, Olivier Rouvière, Gemma Sancho Pardo, Jonathan Richenberg, Ivo G Schoots, J P Michiel Sedelaar, Phillip Stricker, Derya Tilki, Susanne Vahr Lauridsen, Roderick C N van den Bergh, Thomas Van den Broeck, Theodorus H van der Kwast, Henk G van der Poel, Geert J L H van Leenders, Murali Varma, Philippe D Violette, Christopher J D Wallis, Thomas Wiegel, Karen Wilkinson, Fabio Zattoni, James M O N'Dow, Hendrik Van Poppel, Philip Cornford, Nicolas Mottet,

BACKGROUND:There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. OBJECTIVE:To develop consensus statements for all domains of DAT. DESIGN, SETTING, AND PARTICIPANTS:A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association ... Read more >>

Eur. Urol. (European Urology)
[2019, 76(6):790-813]

Cited: 4 times

View full text PDF listing >>



Imaging and T Category for Prostate Cancer in the 8th Edition of the Union for International Cancer Control TNM Classification.

Henk van der Poel, Theo van der Kwast, Katja Aben, Nicolas Mottet, Malcolm Mason,

Eur Urol Oncol (European urology oncology)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations.

Thomas Van den Broeck, Roderick C N van den Bergh, Erik Briers, Philip Cornford, Marcus Cumberbatch, Derya Tilki, Maria De Santis, Stefano Fanti, Nicola Fossati, Silke Gillessen, Jeremy P Grummet, Ann M Henry, Michael Lardas, Matthew Liew, Malcolm Mason, Lisa Moris, Ivo G Schoots, Theodorus van der Kwast, Henk van der Poel, Thomas Wiegel, Peter-Paul M Willemse, Olivier Rouvière, Thomas B Lam, Nicolas Mottet,

Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk ... Read more >>

Eur Urol Focus (European urology focus)
[2020, 6(2):231-234]

Cited: 2 times

View full text PDF listing >>



Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.

Giorgio Gandaglia, Peter Albers, Per-Anders Abrahamsson, Alberto Briganti, James W F Catto, Christopher R Chapple, Francesco Montorsi, Nicolas Mottet, Monique J Roobol, Jens Sønksen, Manfred Wirth, Hendrik van Poppel,

Prostate cancer (PCa) is one of the first three causes of cancer mortality in Europe. Screening in asymptomatic men (aged 55-69yr) using prostate-specific antigen (PSA) is associated with a migration toward lower staged disease and a reduction in cancer-specific mortality. By 20yr after testing, around 100 men need to be ... Read more >>

Eur. Urol. (European urology)
[2019, 76(2):142-150]

Cited: 1 time

View full text PDF listing >>



Evaluation of a new balloon for fetal endoscopic tracheal occlusion in the nonhuman primate model.

Nicolas Sananès, Pierrick Regnard, Nicolas Mottet, Claire Miry, Lyne Fellmann, Laure Haelewyn, Maïa Delaine, Anne Schneider, Christian Debry, Romain Favre,

OBJECTIVE:We developed a new balloon called "Smart-TO," which allows noninvasive and easy unplugging, thanks to a magnetic valve actuated by the magnetic fringe field of a magnetic resonance imaging (MRI) scanner. The objective of this feasibility study was to evaluate the operation of this new balloon in a nonhuman primate ... Read more >>

Prenat. Diagn. (Prenatal diagnosis)
[2019, 39(5):403-408]

Cited: 0 times

View full text PDF listing >>



Reply to Xueliang Zhou and Xinwei Han's Letter to the Editor re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol 2019;75:967-87.

Thomas Van den Broeck, Nicolas Mottet, Thomas Lam,

Eur. Urol. (European Urology)
[2019, 76(1):e16]

Cited: 1 time

View full text PDF listing >>



Advertisement

Disclaimer
1.3605 s